Adenosquamous lung carcinomas: A histologic subtype with poor prognosis

Filosso, Pier Luigi; Ruffini, Enrico; Asioli, Sofia; Giobbe, Roberto; Macrì, Luigia; Bruna, Maria Cristina; Sandri, Alberto; Oliaro, A

doi:10.1016/j.lungcan.2011.01.030

Cited by 94 publications

(92 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In NSCLC, histology is an important parameter resulting in different treatment approaches and prognosis [15]. In contrast to localised disease, where squamous cell histology is generally associated with better survival rates, this does not apply for patients with stage IV disease [15][16][17][18][19]. In an older analysis of three radiation therapy oncology group (RTOG) studies which were performed in the 1970 to 1990s a survival difference between squamous cell histology and small cell histology versus other histologies was demonstrated [20].…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC)

Putora

Ess

Panje

et al. 2015

Clin Exp Metastasis

View full text Add to dashboard Cite

Brain metastases from non-small cell lung cancer (NSCLC) are associated with a poor prognosis. In selected cases, surgical resection of brain metastases may be indicated, but the identification of patients suitable for surgery remains difficult. We collected data on patient and tumour characteristics known or suspected to be associated with survival by chart review. Data was merged with available data from the local cancer registry. We identified 64 NSCLC patients with resected brain metastases. Median overall survival after resection was 9.1 months with only two patients (3%) surviving more than 71 and 80 months. One and 2-year survival were 42 and 12.5%. Median survival for males and patients with more comorbidities was shorter (8 vs. 10 months [p = 0.11] and 6 vs. 9 months [p = 0.06]). Patients with squamous cell carcinomas (33% of the patients) had a significantly worse survival than patients with other histologies (7 vs. 10 months [p = 0.02]) with no patient living longer than 2 years. Squamous cell histology was associated with worse prognosis after resection of brain metastases in patients with non-small cell lung cancer. Histology, among other parameters, may also be taken into account when choosing the appropriate patients for resection of brain metastases.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC)

Putora

Ess

Panje

et al. 2015

Clin Exp Metastasis

View full text Add to dashboard Cite

show abstract

“…The majority of available studies report an aggressive biological behavior of ASCLC (2)(3)(4)(5). In ASCLC, EGFR mutations appear to be important predictive markers for the response to EGFR-tyrosine kinase inhibitors (TKIs), similar to the observed favorable outcome in other cell types of NSCLC (10).…”

Section: Discussionmentioning

confidence: 99%

“…However, the frequency of EGFR abnormalities and the effectiveness of TKIs in EGFR-mutated ASCLC have not yet been completely evaluated. In patients with resectable ASCLC, postoperative platinum-based chemotherapy has significantly improved patient survival and reduced the risk of developing distant metastases (2). Similar to other cell types of NSCLC, it is now widely accepted that postoperative platinum-based chemotherapy is the standard medical treatment in stage IB-IIIA ASCLC (2).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Successful pemetrexed-containing chemotherapy for epidermal growth factor receptor mutation-positive adenosquamous cell carcinoma of the lung: A case report

Watanabe

Tamura

Kagohashi

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Pemetrexed-containing chemotherapy has shown promise in the treatment of non-small-cell lung cancer (NSCLC). However, although adenosquamous cell lung cancer (ASCLC) is a type of NSCLC, the availability of studies investigating its response to pemetrexed-containing chemotherapy is limited. A 66-year-old woman was referred to Mito Medical Center, University of Tsukuba with hemoptysis and a chest computed tomography (CT) scan revealed a large cavitary mass in the lower lobe of the left lung. The patient underwent left lower lobectomy and mediastinal lymph node dissection. The tumor was staged as pT2bN2M0. An epidermal growth factor receptor (EGFR) exon 19 deletion was identified in the adenocarcinomatous as well as the squamous cell carcinomatous components. Despite gefitinib therapy for pulmonary metastases, the patient developed cavitary metastases in both lungs. Therefore, treatment with pemetrexed-containing chemotherapy was initiated. A chest CT scan revealed significant regression of the metastatic lesions in both lungs, with thinning of the walls. The patient remains well and recurrence-free 19 months after the initiation of pemetrexed-containing chemotherapy. Therefore, the clinical response of EGFR mutation-positive ASCLC to pemetrexed-containing chemotherapy was promising, suggesting pemetrexed to be one of the key drugs for this subset of ASCLC patients.

show abstract

“…Postoperative adjuvant platinum-based chemotherapy (even for stage Ⅰ patients) reduced the risk of developing distant metastasis and improved patient survival [2] . Our current study showed that postoperative treatment (such as chemotherapy and radiation) improved the survival of ASC patients.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological characteristics and prognosis of patients with adenosquamous lung carcinoma

Guo

Jia

Shao

et al. 2015

J. Huazhong Univ. Sci. Technol. [Med. Sci.]

View full text Add to dashboard Cite

This study was aimed to characterize clinicopathological features and prognosis of patients with adenosquamous lung carcinoma (ASC). Among the 2531 patients with lung cancer who underwent surgery between January 2000 and June 2012 in our hospital, 59 were histologically diagnosed as having ASC. The clinicopathological features and follow-up data of ASC patients were collected and analyzed statistically. Superior lobectomy was accomplished in 40 patients, middle and inferior lobectomy in 3, lobectomy plus partial resection of contralateral lung in 5, partial lung resection in 4, and pneumonectomy in 7. Moreover, 22 cases were found to be adenocarcinoma-predominant, and 18 to be squamous cell carcinoma-predominant. The median survival time was 13.6 months, and the 1-, 3-, and 5-year survival rates were 59.9%, 36.4% and 31.2%, respectively. Of the 52 cases with tissue specimens available, 11 had an EGFR mutation (21.2%) and 2 had a KRAS mutation (3.8%). Multivariate analysis showed that histology subtype, pleural invasion, TNM stage, and postoperative treatment were all independent prognostic factors. The data from the current study demonstrated that SCC-predominant histology represents a better prognosis of ASC. Histology subtype, pleural invasion, TNM stage, and postoperative treatment are independent prognostic factors for ASC and adjuvant therapy may help control the disease.

show abstract

Adenosquamous lung carcinomas: A histologic subtype with poor prognosis

Cited by 94 publications

References 13 publications

Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC)

Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC)

Successful pemetrexed-containing chemotherapy for epidermal growth factor receptor mutation-positive adenosquamous cell carcinoma of the lung: A case report

Clinicopathological characteristics and prognosis of patients with adenosquamous lung carcinoma

Contact Info

Product

Resources

About